Anzeige
Mehr »
Login
Donnerstag, 18.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Kurze Gold-Preis-Konsolidierung zum Einstieg in diese Aktie nutzen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
583 Leser
Artikel bewerten:
(2)

Veeva Systems: Veeva R&D and Quality Summit Europe Brings Pharma Industry Together to Streamline Drug Development

Life sciences leaders convene to break barriers in advancing digital trials and product development

BARCELONA, Spain, June 22, 2022 /PRNewswire/ -- One of the largest European events of its kind, Veeva R&D and Quality Summit Europe recently gathered more than 500 life sciences leaders in Zurich to discuss new approaches for advancing digital trials and driving transformation in clinical, quality, regulatory, and safety.

Veeva Systems

"The exchange of ideas with my peers at Veeva R&D and Quality Summit was invaluable," said Martijn van de Leur, global pharmacovigilance leader at Biomapas. "It is truly a community of like-minded professionals who are passionate about improving health outcomes for patients through innovation."

Steve Guise, CIO, Roche Pharmaceuticals division, kicked off the event with his keynote highlighting the company's ambitious goal of generating three to five times the benefit to patients at half the cost to society by leveraging a modern technology foundation.

Attendees learned about industry-leading strategies to streamline processes across the product lifecycle, such as:

  • GSK establishing a connected clinical ecosystem to shorten cycle times for early trial processes, simplify data management, and reduce EDC build time by half
  • LEO Pharma unifying data to enable simpler processes, automation, and proactive patient safety
  • Idorsia, Novo Nordisk, and TFS HealthScience building a foundation for digital clinical trials to link sponsors, research sites, and patients
  • Jazz Pharmaceuticals bringing together quality data, content, and processes to scale operations

"The deep knowledge and experience leaders brought to the Veeva R&D and Quality Summit Europe helped people understand what it takes to create more efficient, faster ways to bring medicines to patients," said Chris Moore, president of Veeva Europe. "These innovative strategies can ultimately drive the whole industry forward."

Life sciences industry professionals who couldn't attend the event can watch Veeva R&D and Quality Summit Europe keynote and sessions.

Additional Information
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu

About Veeva Systems

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.

Contact:

Jeremy Whittaker
Veeva Systems
+49 6950955486
jeremy.whittaker@veeva.com

Logo - https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2022 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.